{
  "abstract": "Background/Objectives: To evaluate uveitis risk among biologic users with IBD using signal detection and nationwide outcome data. Methods: We performed a disproportionality analysis of the FDA Adverse Event Reporting System and a retrospective nationwide cohort study of 7862 Korean patients with IBD who initiated adalimumab, vedolizumab, or ustekinumab between 2015 and 2024. Incident uveitis, identified by diagnostic codes, was compared before and after biologic initiation in exploratory analyses to calculate incidence rate ratios, with post-exposure divided into 0–90 and beyond 90 days; cumulative incidence and multivariable Cox regression were also assessed. Post-switch uveitis risk was compared between patients switching from adalimumab to vedolizumab or ustekinumab. Results: Disproportionality analysis identified positive signals for adalimumab (reporting odds ratio, 4.97) and vedolizumab (2.80), but not ustekinumab (0.63). No statistically significant increase in uveitis incidence was observed after biologic initiation in the cohort. No events occurred within 90 days of vedolizumab or ustekinumab initiation; beyond 90 days, incidence rate ratios were 1.3 (95% confidence interval [CI], 0.6–2.9) and 0.6 (95% CI, 0.2–1.7). Adjusted cumulative incidence at the end of follow-up was 1.1%, 0.6%, and 0.2% for adalimumab, vedolizumab, and ustekinumab, with no significant differences on Cox regression. Post-switch risk was similar between vedolizumab and ustekinumab (hazard ratio, 0.88; 95% CI, 0.14–5.58). Conclusions: Pharmacovigilance signals for adalimumab and vedolizumab were not reproduced in a nationwide cohort, in which no statistically significant difference in uveitis risk was detected among the three biologics. Given the small number of events and potential selection bias, these descriptive findings do not exclude clinically important differences between treatments.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Ophthalmology, Hanyang University Guri Hospital, Guri 11923, Republic of Korea",
    "Department of Pre-Medicine, College of Medicine, and Biostatistics Laboratory, Medical Research Collaborating Center, Hanyang University, Seoul 04763, Republic of Korea",
    "College of Pharmacy, Hanyang University, Ansan 15588, Republic of Korea",
    "Department of Ophthalmology, Hanyang University Hospital, Hanyang University College of Medicine, Seoul 04763, Republic of Korea"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Sunjin Hwang",
      "orcid": "0009-0009-5142-8334"
    },
    {
      "affs": [
        1
      ],
      "name": "Jiyeong Kim",
      "orcid": "0000-0002-7969-1419"
    },
    {
      "affs": [
        0
      ],
      "name": "Eun Hee Hong",
      "orcid": "0000-0001-8413-1929"
    },
    {
      "affs": [
        2
      ],
      "name": "Jee-Eun Chung",
      "orcid": "0000-0001-5608-1530"
    },
    {
      "affs": [
        3
      ],
      "name": "Seong Joon Ahn",
      "orcid": "0000-0002-4545-8344"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/0gydcck1r4537.bib",
  "cited_by": 0,
  "doi": "10.3390/jcm15218291",
  "fulltext_url": null,
  "id": "0gydcck1r4537",
  "issns": [
    "2077-0383"
  ],
  "landing_url": "https://www.mdpi.com/2077-0383/15/21/8291",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "1311|Inflammatory Bowel Disease"
    ]
  ],
  "openalex": "W7223788204",
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-24",
  "publisher": "MDPI AG",
  "ris": "https://research.draconitic.com/paper/0gydcck1r4537.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:01Z",
      "native_id": "10.3390/jcm15218291",
      "source": "crossref",
      "url": "https://www.mdpi.com/2077-0383/15/21/8291"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "openalex:1311|Inflammatory Bowel Disease",
      "subfield": "genetics-genomics"
    }
  ],
  "title": "Uveitis in Patients with Inflammatory Bowel Disease: Pharmacovigilance Signal Detection and Nationwide Claims-Based Evaluation",
  "title_text": "Uveitis in Patients with Inflammatory Bowel Disease: Pharmacovigilance Signal Detection and Nationwide Claims-Based Evaluation",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:01Z",
  "url": "https://research.draconitic.com/paper/0gydcck1r4537",
  "venue": "Journal of Clinical Medicine",
  "versions": []
}